Verrica Q2 2026 Earnings: YCANTH Demand Rises as Losses Widen

Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q2 2026 revenue of $5.9 million, down 53.9% from $12.7 million a year earlier, and a diluted GAAP loss of $0.62 per share versus income of $0.02 per share. U.S. YCANTH net product revenue increased 12.3%, but the absence of an $8.0 million prior-year collaboration milestone and higher development and commercial spending pushed the company back into a quarterly loss.

Core Earnings Data

The revenue decline primarily reflected license and collaboration revenue falling to $0.8 million from $8.2 million. The prior-year figure included a one-time $8.0 million milestone from Torii, while Q2 2026 collaboration revenue mainly came from commercial supply for YCANTH’s launch in Japan.

At the same time, total expenses rose 69.4%. R&D spending related to the Phase 3 common-warts program was the largest contributor, alongside higher commercial spending and a $1.7 million legal settlement expense net of insurance recovery.

Non-GAAP results exclude stock-based compensation, the legal settlement and certain other non-cash or one-time items specified by the company.

YCANTH Demand Growth Did Not Offset the Milestone Comparison

YCANTH dispensed applicator units reached a quarterly record of 19,626, increasing 46.1% year over year and 28.3% sequentially. U.S. net product revenue grew more slowly, rising 12.3% year over year to $5.1 million and 18.7% from the preceding quarter.

The two measures cover different points in the commercial channel. Dispensed units reflect downstream demand, while Verrica said the product-revenue increase was primarily related to deliveries to distribution partners. The company did not provide enough information to attribute the difference in growth rates to pricing, inventory timing or other specific factors.

Despite the higher product revenue, its $0.6 million year-over-year increase was not enough to offset the $7.4 million decline in license and collaboration revenue. As a result, YCANTH’s commercial progress was obscured in the consolidated revenue comparison by the prior-year milestone payment.

Spending, Cash, and Liquidity

Selling, general and administrative expense increased to $10.3 million from $8.9 million. Excluding stock-based compensation, the increase was primarily due to expanded commercial spending associated with the larger sales force.

R&D expense rose to $6.0 million from $1.8 million, mainly because of the Phase 3 common-warts program. Verrica said this program’s Q2 expense did not reduce its cash balance because Torii will fund the first $40 million of program payments under the companies’ collaboration agreement. The expense nevertheless reduced reported GAAP and non-GAAP earnings.

The company also recorded a $1.7 million legal settlement expense after insurance recovery. Interest expense declined to $0.2 million from $2.1 million following the November 2025 settlement and termination of the OrbiMed debt facility, but that reduction was not sufficient to offset higher operating costs.

Cash stood at $11.2 million on June 30, 2026, down by approximately $18.9 million from December 31, 2025. Total liabilities increased to $31.7 million from $22.4 million over the same period, while stockholders’ equity declined to $4.3 million from $24.7 million.

On August 6, Verrica announced a credit facility of up to $27.5 million with an entity controlled by Chairman and largest shareholder Paul B. Manning. Management said full availability of the facility, together with the current operating plan, could extend the cash runway into 2028. That runway estimate is conditional on the company being able to access the full facility.

Clinical Development Milestones

Verrica continued enrolling patients in COVE-2, the first pivotal study evaluating YCANTH for common warts. During the quarter, the first U.S. and Japanese patients were dosed in COVE-3, the second pivotal trial. Topline data from the global Phase 3 program are currently expected in mid-2027.

For VP-315 in basal cell carcinoma, the company presented Phase 2 data in May that included evidence of potential effects in both treated and untreated lesions. Verrica said it is continuing Phase 3 readiness work, but the release did not provide a Phase 3 start date.

Recent Insider Transactions

The supplied insider dataset reported no insider purchases or sales during the most recent six-month period and listed total insider holdings of 8.37 million shares. The latest two-year records were concentrated in November 2025 and include both direct and indirect transactions; they should not be treated by themselves as evidence of insiders’ outlook for the company.

Reported values are reproduced from the supplied insider data; share counts were not provided for these individual entries.

Risks Investors Need to Watch

• Liquidity remains dependent on additional financing access. Verrica ended the quarter with $11.2 million in cash, and its stated runway into 2028 assumes full availability of the new $27.5 million credit facility.
• Commercial growth has not yet covered the cost base. U.S. YCANTH revenue increased, but total quarterly expenses of $19.0 million remained substantially above total revenue of $5.9 million.
• Collaboration revenue can be volatile. The year-over-year revenue decline demonstrates how one-time milestones can materially affect reported results even when product revenue is growing.
• Pipeline timing and outcomes are material. The common-warts expansion depends on the ongoing COVE-2 and COVE-3 trials, with topline data not expected until mid-2027. VP-315 also remains in Phase 3 readiness activities rather than pivotal development.

Summary

Verrica’s Q2 2026 results showed rising YCANTH demand and higher U.S. product revenue, but consolidated revenue fell because the prior-year quarter contained a large one-time milestone. Increased Phase 3 spending, commercial investment and the legal settlement widened losses, leaving liquidity and access to the new credit facility as important near-term considerations. The next major operating test is whether YCANTH revenue can scale against the company’s expense base while the common-warts program advances toward mid-2027 data.